[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Streptokinase.]
[J01GA01, streptomycin, Sibutramine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sibutramine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01CG01, sulbactam, Sibutramine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Sulfinpyrazone.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Sibutramine.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Sibutramine.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Azapropazone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Sibutramine.]
[R03CC03, terbutaline, Sibutramine may increase the tachycardic activities of Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dabigatran etexilate.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tetracaine is combined with Sibutramine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Sibutramine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Sibutramine.]
[L04AX02, thalidomide, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Sibutramine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Sibutramine.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Sibutramine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Sibutramine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Sibutramine.]
[G04BE06, moxisylyte, Sibutramine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Sibutramine.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Sibutramine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Sibutramine.]
[B01AC05, ticlopidine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Sibutramine.]
[S01ED01, timolol, The serum concentration of Timolol can be increased when it is combined with Sibutramine.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01AA12, tobramycin, Sibutramine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[V04CA01, tolbutamide, Sibutramine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Sibutramine.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the serotonergic activities of Sibutramine.]
[C01DX11, trapidil, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Sibutramine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Sibutramine.]
[C03AA06, trichlormethiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Sibutramine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sibutramine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Sibutramine.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sibutramine.]
[N04AA01, trihexyphenidyl, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Sibutramine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Sibutramine.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Sibutramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Sibutramine.]
[A03BB01, butylscopolamine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Sibutramine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Sibutramine.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Sibutramine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Sibutramine.]
[R03DX07, roflumilast, Sibutramine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Sibutramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Sibutramine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Sibutramine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Sibutramine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Sibutramine can be decreased when combined with Telaprevir.]
[B01AD04, urokinase, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Urokinase.]
[S01AA28, vancomycin, Sibutramine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Sibutramine.]
[B01AF01, rivaroxaban, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Rivaroxaban.]
[R03AC18, indacaterol, Sibutramine may increase the tachycardic activities of Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Sibutramine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Sibutramine can be decreased when combined with Viloxazine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Warfarin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sibutramine.]
[J05AE02, indinavir, The metabolism of Sibutramine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Sibutramine.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Sibutramine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Sibutramine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Sibutramine can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Lepirudin.]
[A02BC04, rabeprazole, Sibutramine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Sibutramine is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Sibutramine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Sibutramine may increase the antiplatelet activities of Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Sibutramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Sibutramine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Sibutramine.]
[J02AC03, voriconazole, The metabolism of Sibutramine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Sibutramine.]
[S01FA01, atropine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[B03XA04, peginesatide, Sibutramine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Sibutramine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Sibutramine.]
[G04BD12, mirabegron, Sibutramine may increase the tachycardic activities of Mirabegron.]
[V03AX03, cobicistat, The metabolism of Sibutramine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Sibutramine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Sibutramine can be decreased when it is combined with Enzalutamide.]
[B01AX01, defibrotide, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Defibrotide.]
[C01CA18, octopamine, Sibutramine may increase the tachycardic activities of Octopamine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Sibutramine.]
[D02BA02, octinoxate, Sibutramine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Sibutramine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[N04BD02, rasagiline, Rasagiline may increase the serotonergic activities of Sibutramine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Sibutramine.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Sibutramine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Sibutramine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Sibutramine.]
[V08CA11, gadofosveset, Sibutramine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[B01AF02, apixaban, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Apixaban.]
[A16AX08, teduglutide, Sibutramine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Sibutramine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Sibutramine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Sibutramine.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Sibutramine.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Tegaserod is combined with Sibutramine.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Sibutramine.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Sibutramine.]
[L03AA12, ancestim, Sibutramine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of bleeding can be increased when Celecoxib is combined with Sibutramine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sibutramine.]
[N04AC01, benztropine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Sibutramine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Benzydamine.]
[L01EE01, trametinib, Sibutramine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Sibutramine.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sibutramine.]
[V09AX05, florbetapir F-18, Sibutramine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Sibutramine is combined with Levomilnacipran.]
[A10BJ03, lixisenatide, Sibutramine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Sibutramine may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Sibutramine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Sibutramine.]
[J05AP05, simeprevir, The metabolism of Sibutramine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Sibutramine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Sibutramine.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Sibutramine may increase the tachycardic activities of Droxidopa.]
[C07AB04, acebutolol, The serum concentration of Acebutolol can be increased when it is combined with Sibutramine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Sibutramine.]
[A16AA07, metreleptin, The metabolism of Sibutramine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Sibutramine may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Sibutramine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Sibutramine.]
[B01AE03, argatroban, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Argatroban.]
[V03AB34, fomepizole, Sibutramine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Sibutramine may increase the tachycardic activities of Bethanidine.]
[B01AC26, vorapaxar, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Vorapaxar.]
[A03BA03, hyoscyamine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Sibutramine.]
[R03AC19, olodaterol, Sibutramine may increase the tachycardic activities of Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[D11AA01, glycopyrronium, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05CM19, suvorexant, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Sibutramine.]
[A06AH03, naloxegol, The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Sibutramine.]
[N04AA02, biperiden, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[S03AA06, gentamicin, Sibutramine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Edoxaban.]
[N06AX11, mirtazapine, Sibutramine may increase the serotonergic activities of Mirtazapine.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A03AA09, difemerine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Eluxadoline is combined with Sibutramine.]
[B01AC25, cangrelor, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Cangrelor.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sibutramine.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Sibutramine.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Sibutramine.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sibutramine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Sibutramine.]
[V03AB37, idarucizumab, Sibutramine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The metabolism of Sibutramine can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sibutramine.]
[L01XG03, ixazomib, Sibutramine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[M04AB05, lesinurad, Sibutramine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Sibutramine.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Sibutramine.]
[L01XX52, venetoclax, The metabolism of Sibutramine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Sibutramine.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sibutramine.]
[A02AD05, aluminum magnesium silicate, Sibutramine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Sibutramine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sibutramine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Sibutramine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Sibutramine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sibutramine.]
[C07AA19, bupranolol, The serum concentration of Bupranolol can be increased when it is combined with Sibutramine.]
[N07BC01, buprenorphine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Sibutramine.]
[L01XX27, arsenic trioxide, Sibutramine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Sibutramine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Sibutramine.]
[S01GX07, azelastine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01EF02, ribociclib, The metabolism of Sibutramine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Balsalazide.]
[R03CC12, bambuterol, Sibutramine may increase the tachycardic activities of Bambuterol.]
[A06AH05, naldemedine, Sibutramine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Sibutramine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Sibutramine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Sibutramine.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sibutramine.]
[P01CA02, benznidazole, Sibutramine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Sibutramine.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Sibutramine can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Sibutramine.]
[N07XX13, valbenazine, Sibutramine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01EX10, midostaurin, The metabolism of Sibutramine can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Sibutramine.]
[N04BD03, safinamide, Safinamide may increase the serotonergic activities of Sibutramine.]
[J01MA23, delafloxacin, Sibutramine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Sibutramine.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Sibutramine.]
[R03AC17, bitolterol, Sibutramine may increase the tachycardic activities of Bitolterol.]
[J05AG03, efavirenz, The metabolism of Sibutramine can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Sibutramine.]
[N04AA11, bornaprine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Sibutramine.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Sibutramine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Sibutramine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Sibutramine.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Butriptyline is combined with Sibutramine.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Sibutramine.]
[R06AX18, acrivastine, Sibutramine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, The metabolism of Sibutramine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Sibutramine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Sibutramine.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Sibutramine.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Sibutramine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Sibutramine.]
[L04AA37, baricitinib, Sibutramine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01GB14, plazomicin, Sibutramine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The serum concentration of Celiprolol can be increased when it is combined with Sibutramine.]
[L01XX62, ivosidenib, The metabolism of Sibutramine can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Sibutramine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Sibutramine can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Sibutramine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Sibutramine.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sibutramine.]
[D08AE05, chloroxylenol, Sibutramine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Lornoxicam.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Sibutramine.]
[R03BB08, revefenacin, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L01EX13, gilteritinib, The therapeutic efficacy of Sibutramine can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, Sibutramine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Caplacizumab.]
[B01AC23, cilostazol, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Sibutramine.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Sibutramine is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Sibutramine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Sibutramine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Sibutramine.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Sibutramine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Sibutramine.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Sibutramine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sibutramine.]
[N07XX11, pitolisant, The serum concentration of Sibutramine can be decreased when it is combined with Pitolisant.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Sibutramine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Sibutramine.]
[N03AX25, cenobamate, The serum concentration of Sibutramine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M09AX08, golodirsen, Sibutramine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sibutramine.]
[S01XA12, dexpanthenol, Sibutramine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Sibutramine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lemborexant is combined with Sibutramine.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Sibutramine.]
[J05AE05, amprenavir, The metabolism of Sibutramine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Sibutramine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Sibutramine.]
[R02AA03, dichlorobenzyl alcohol, Sibutramine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Sibutramine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Sibutramine.]
[N02AA08, dihydrocodeine, The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Sibutramine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Sibutramine.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Rofecoxib.]
[C08CA16, clevidipine, Sibutramine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The metabolism of Sibutramine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Sibutramine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sibutramine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Sibutramine.]
[A03AA08, dihexyverine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, Sibutramine may increase the tachycardic activities of Dopexamine.]
[G04BD09, trospium, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Droxicam.]
[V08CA05, mangafodipir, Sibutramine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Sibutramine.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Sibutramine.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Sibutramine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Remimazolam is combined with Sibutramine.]
[L04AC19, satralizumab, The serum concentration of Sibutramine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Sibutramine is combined with Oliceridine.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Sibutramine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sibutramine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sibutramine.]
[C03BA04, chlorthalidone, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Sibutramine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Sibutramine.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Ethenzamide.]
[N02BA03, choline salicylate, Sibutramine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Sibutramine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sibutramine.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Sibutramine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Sibutramine can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Sibutramine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Sibutramine can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Sibutramine.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Sibutramine.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Fenbufen.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Sibutramine is combined with Fenozolone.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02BG07, flupirtine, Sibutramine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, Sibutramine may increase the tachycardic activities of Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Sibutramine.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Sibutramine.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Sibutramine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L01XX73, sotorasib, The serum concentration of Sibutramine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Sibutramine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Sibutramine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Citalopram is combined with Sibutramine.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AB03, ioflupane I-123, Sibutramine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[V09AA01, technetium Tc 99m exametazime, Sibutramine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Sibutramine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Sibutramine.]
[R03CC13, clenbuterol, Sibutramine may increase the tachycardic activities of Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Sibutramine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Sibutramine.]
[B01AD11, tenecteplase, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sibutramine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Clomipramine is combined with Sibutramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Sibutramine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Sibutramine.]
[C01EB24, mavacamten, The serum concentration of Sibutramine can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Sibutramine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Sibutramine.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Sibutramine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Sibutramine.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Sibutramine.]
[J01GB12, arbekacin, Sibutramine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Sibutramine.]
[H01AC08, somatrogon, The metabolism of Sibutramine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Sibutramine.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of serotonin syndrome can be increased when Codeine is combined with Sibutramine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Sibutramine.]
[M04AC01, colchicine, Sibutramine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Sibutramine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Sibutramine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Sibutramine.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Sibutramine.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Sibutramine can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Sibutramine.]
[J05AB14, valganciclovir, Sibutramine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Sibutramine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Sibutramine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Sibutramine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Sibutramine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Sibutramine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Valdecoxib.]
[A03AX10, isometheptene, Sibutramine may increase the tachycardic activities of Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sibutramine.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Sibutramine can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Sibutramine.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Kebuzone.]
[J02AC04, posaconazole, The metabolism of Sibutramine can be decreased when combined with Posaconazole.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Sibutramine.]
[S01GX02, levocabastine, The risk or severity of adverse effects can be increased when Levocabastine is combined with Sibutramine.]
[N07BC04, lofexidine, The therapeutic efficacy of Sibutramine can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Sibutramine.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Sibutramine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[A03AA04, mebeverine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Sibutramine.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Sibutramine is combined with Mefenorex.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Sibutramine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Sibutramine.]
[N04AA03, methixene, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, Sibutramine may increase the tachycardic activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Sibutramine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Sibutramine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Melperone is combined with Sibutramine.]
[C03AA07, cyclopenthiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the serotonergic activities of Sibutramine.]
[S01XA18, cyclosporine, The metabolism of Sibutramine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the serotonergic activities of Sibutramine.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Sibutramine can be decreased when used in combination with Cyproheptadine.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Sibutramine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Sibutramine may increase the tachycardic activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Sibutramine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Sibutramine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Sibutramine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Nabumetone.]
[N07BB05, nalmefene, Sibutramine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Sibutramine.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Sibutramine.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Sibutramine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Sibutramine.]
[C01DX16, nicorandil, Sibutramine may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Sibutramine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sibutramine.]
[C01CA05, norfenefrine, Sibutramine may increase the tachycardic activities of Norfenefrine.]
[R05DA06, normethadone, The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Sibutramine.]
[B01AX05, fondaparinux, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Escitalopram.]
[G04BD08, solifenacin, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Sibutramine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Desmopressin.]
[V04CH02, indigo carmine, Sibutramine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Sibutramine.]
[S03BA01, dexamethasone, The metabolism of Sibutramine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Sibutramine.]
[N04AA08, dexetimide, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Sibutramine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sibutramine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Sibutramine.]
[N02AC01, dextromoramide, The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Sibutramine.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Sibutramine.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Sibutramine.]
[B01AC04, clopidogrel, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Sibutramine.]
[P03AC04, permethrin, Sibutramine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Sibutramine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Sibutramine.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Sibutramine.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dibenzepin is combined with Sibutramine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Sibutramine.]
[R05DA08, pholcodine, Sibutramine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A03AA07, dicyclomine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Sibutramine.]
[A03AB14, pipenzolate, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, Sibutramine may increase the tachycardic activities of Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Sibutramine.]
[C08CA03, isradipine, The metabolism of Sibutramine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Sibutramine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Diflunisal.]
[C01AA05, digoxin, Sibutramine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sibutramine.]
[N02AA03, hydromorphone, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Sibutramine.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Sibutramine can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Sibutramine.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pramocaine is combined with Sibutramine.]
[C08DB01, diltiazem, The metabolism of Sibutramine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sibutramine.]
[V03AB09, dimercaprol, Sibutramine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Sibutramine.]
[R06AB03, dimethindene, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Sibutramine may increase the tachycardic activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Sibutramine.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sibutramine.]
[A07DA01, diphenoxylate, The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Sibutramine.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Sibutramine.]
[B01AC07, dipyridamole, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Sibutramine.]
[B01AD10, drotrecogin alfa, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Quinupramine is combined with Sibutramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Sibutramine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Sibutramine.]
[R03CC14, reproterol, Sibutramine may increase the tachycardic activities of Reproterol.]
[S01AX06, resorcinol, Sibutramine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Sibutramine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Sibutramine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Sibutramine.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Sibutramine.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Sibutramine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sibutramine.]
[A04AD12, aprepitant, The metabolism of Sibutramine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Ketorolac.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Salsalate.]
[R03AC12, salmeterol, Sibutramine may increase the tachycardic activities of Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Sibutramine.]
[C01CA07, dobutamine, Sibutramine may increase the tachycardic activities of Dobutamine.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Sibutramine.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Sibutramine.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Sertraline is combined with Sibutramine.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Sibutramine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[S01AA13, fusidic acid, The metabolism of Sibutramine can be decreased when combined with Fusidic acid.]
[N07XX04, sodium oxybate, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Sibutramine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[A12CA02, sodium sulfate, Sibutramine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Sibutramine.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Sibutramine.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Sibutramine.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Tenoxicam.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Sibutramine.]
[S01GA02, tetrahydrozoline, Sibutramine may increase the tachycardic activities of Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Sibutramine.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Sibutramine.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Sibutramine.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Sibutramine.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Sibutramine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Sibutramine.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the serotonergic activities of Sibutramine.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Sibutramine.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Sibutramine is combined with Tramazoline.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Sibutramine.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Sibutramine.]
[A03AB08, tridihexethyl, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Triflusal.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Sibutramine.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Sibutramine.]
[N04AA12, tropatepine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Troxerutin.]
[R03CC11, tulobuterol, Sibutramine may increase the tachycardic activities of Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Sibutramine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Sibutramine.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Sibutramine.]
[S01FB02, ephedrine, Sibutramine may increase the tachycardic activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Sibutramine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Venlafaxine.]
[C01CX07, xamoterol, Sibutramine may increase the tachycardic activities of Xamoterol.]
[S01GA03, xylometazoline, Sibutramine may increase the tachycardic activities of Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Sibutramine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, Sibutramine may increase the tachycardic activities of Epinephrine.]
[N05CF02, zolpidem, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Sibutramine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Zopiclone is combined with Sibutramine.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Sibutramine.]
[B01AD03, anistreplase, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Anistreplase.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Sibutramine.]
[B01AC11, iloprost, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Sibutramine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Sibutramine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sibutramine.]
[N02CA02, ergotamine, The metabolism of Sibutramine can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Sibutramine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Sibutramine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Sibutramine.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sibutramine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N04AA05, profenamine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Sibutramine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Sibutramine.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Sibutramine.]
[C01CA01, etilefrine, Sibutramine may increase the tachycardic activities of Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Sibutramine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Sibutramine.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[R06AX12, terfenadine, The metabolism of Sibutramine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Sibutramine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Sibutramine.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sibutramine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Sibutramine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dextran.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Fenoprofen.]
[R03CC04, fenoterol, Sibutramine may increase the tachycardic activities of Fenoterol.]
[N02AB03, fentanyl, The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Sibutramine.]
[R03CC02, albuterol, Sibutramine may increase the tachycardic activities of Salbutamol.]
[B01AD05, plasmin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Fibrinolysin.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[G04BD02, flavoxate, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Sibutramine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[V03AB25, flumazenil, Sibutramine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Sibutramine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Sibutramine.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Melitracen is combined with Sibutramine.]
[V03AZ01, ethanol, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Sibutramine.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Sibutramine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Sibutramine.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sibutramine.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L01BC03, tegafur, Sibutramine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, Sibutramine may increase the tachycardic activities of Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Sibutramine.]
[G01AX06, furazolidone, Furazolidone may increase the serotonergic activities of Sibutramine.]
[J05AE10, darunavir, The metabolism of Sibutramine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Sibutramine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Sibutramine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Sibutramine.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Sibutramine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Sibutramine.]
[C10AB04, gemfibrozil, Sibutramine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Sibutramine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Sibutramine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Sibutramine.]
[N01AH02, alfentanil, The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Sibutramine.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sibutramine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Sibutramine.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sibutramine.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C07AB09, esmolol, The serum concentration of Esmolol can be increased when it is combined with Sibutramine.]
[M01CB04, aurothioglucose, Sibutramine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Sibutramine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Fluindione.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01EX01, guanethidine, Sibutramine may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Sibutramine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Sibutramine.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Sibutramine.]
[N06BX13, idebenone, Sibutramine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Sibutramine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Sibutramine.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Heparin.]
[G03DC01, allylestrenol, Sibutramine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Mesalazine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Sibutramine.]
[R03CC05, hexoprenaline, Sibutramine may increase the tachycardic activities of Hexoprenaline.]
[C08CA10, nilvadipine, The metabolism of Sibutramine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Nimesulide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C02DB02, hydralazine, Sibutramine may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Sibutramine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[G04BD06, propiverine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Sibutramine.]
[B05AA07, hetastarch, Sibutramine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[C02AC06, rilmenidine, Sibutramine may increase the tachycardic activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Ibuprofen.]
[B05XA08, sodium acetate, Sibutramine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Sodium citrate.]
[L01AA06, ifosfamide, Sibutramine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Sibutramine.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Sibutramine.]
[R01AD07, tixocortol, Sibutramine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Sibutramine.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Indomethacin.]
[A11HA07, inositol, Sibutramine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Sibutramine is combined with Milnacipran.]
[A03AA30, piperidolate, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Sibutramine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Articaine is combined with Sibutramine.]
[A10BH01, sitagliptin, Sibutramine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Sibutramine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Sibutramine.]
[R06AE01, buclizine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Sibutramine.]
[C03BA02, quinethazone, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Quinethazone.]
[V03AB01, ipecac, Sibutramine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Iprindole is combined with Sibutramine.]
[N06AF05, iproniazid, Iproniazid may increase the serotonergic activities of Sibutramine.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Sibutramine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the serotonergic activities of Sibutramine.]
[R03CC06, isoetharine, Sibutramine may increase the tachycardic activities of Isoetharine.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Sibutramine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Sibutramine.]
[J04AC01, isoniazid, The metabolism of Sibutramine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Sibutramine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Sibutramine may increase the tachycardic activities of Isoprenaline.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C04AA01, isoxsuprine, Sibutramine may increase the tachycardic activities of Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Bivalirudin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Sibutramine.]
[S01AA24, kanamycin, Sibutramine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Sibutramine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Sibutramine.]
[B01AC22, prasugrel, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Sibutramine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Sibutramine.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Ketoprofen.]
[C01CA22, arbutamine, Sibutramine may increase the tachycardic activities of Arbutamine.]
[N04BC09, rotigotine, Sibutramine may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The serum concentration of Labetalol can be increased when it is combined with Sibutramine.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Sibutramine.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Sibutramine.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Sibutramine.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sibutramine.]
[S01AA21, amikacin, Sibutramine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Sibutramine.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lofepramine is combined with Sibutramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Sibutramine.]
[C10AA02, lovastatin, The metabolism of Sibutramine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Sibutramine.]
[B05XA11, magnesium chloride, Sibutramine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Sibutramine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Sibutramine can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Sibutramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Sibutramine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Sibutramine.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Sibutramine.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Sibutramine.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Sibutramine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Sibutramine.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Sibutramine.]
[C01CA11, mephentermine, Sibutramine may increase the tachycardic activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Sibutramine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sibutramine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Sibutramine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Sibutramine.]
[N02AX05, meptazinol, The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Sibutramine.]
[G04BX16, tiopronin, Sibutramine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Sibutramine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Sibutramine.]
[C01CA09, metaraminol, Sibutramine may increase the tachycardic activities of Metaraminol.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Sibutramine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Sibutramine.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Sibutramine.]
[A03AB07, methantheline, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Sibutramine.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Sibutramine.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Sibutramine.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Sibutramine.]
[H03BB02, methimazole, The metabolism of Sibutramine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Sibutramine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Sibutramine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Sibutramine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Sibutramine.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Sibutramine may increase the tachycardic activities of Methoxamine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sibutramine.]
[C03AA08, methyclothiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Methyclothiazide.]
[C02AB01, methyldopa, Sibutramine may increase the tachycardic activities of Methyldopa.]
[V04CG05, methylene blue, Sibutramine may increase the serotonergic activities of Methylene blue.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Sibutramine.]
[G03EK01, methyltestosterone, Sibutramine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Sibutramine.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Sibutramine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sibutramine.]
[C03BA08, metolazone, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Metolazone.]
[C07AB02, metoprolol, The serum concentration of Metoprolol can be increased when it is combined with Sibutramine.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Sibutramine.]
[S02AA13, miconazole, The metabolism of Sibutramine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Sibutramine.]
[C01CA17, midodrine, Sibutramine may increase the tachycardic activities of Midodrine.]
[B01AB10, tinzaparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[L01XX23, mitotane, The metabolism of Sibutramine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Sibutramine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Sibutramine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Sibutramine.]
[N02AA01, morphine, The risk or severity of serotonin syndrome can be increased when Morphine is combined with Sibutramine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Sibutramine.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Sibutramine may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Sibutramine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Sibutramine.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Sibutramine.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Sibutramine.]
[N03AB05, fosphenytoin, The metabolism of Sibutramine can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Sibutramine.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N04BC04, ropinirole, Sibutramine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Sibutramine.]
[N02AF02, nalbuphine, The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Sibutramine.]
[V03AB15, naloxone, The metabolism of Sibutramine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Sibutramine.]
[S01GA01, naphazoline, Sibutramine may increase the tachycardic activities of Naphazoline.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Sibutramine.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Duloxetine is combined with Sibutramine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Sibutramine.]
[S03AA01, neomycin, Sibutramine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Sibutramine.]
[B01AC17, tirofiban, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Tirofiban.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Sibutramine.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[L03AX16, plerixafor, Sibutramine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Sibutramine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Sibutramine is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C01CE01, inamrinone, Sibutramine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, Nialamide may increase the serotonergic activities of Sibutramine.]
[C08CA04, nicardipine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Sibutramine.]
[C08CA05, nifedipine, Sibutramine may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Niflumic acid.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Sibutramine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Sibutramine.]
[N04BC05, pramipexole, Sibutramine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Sibutramine.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Sibutramine.]
[C01CA03, norepinephrine, Sibutramine may increase the tachycardic activities of Norepinephrine.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Sibutramine.]
[B01AC16, eptifibatide, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Eptifibatide.]
[G02CA02, nylidrin, Sibutramine may increase the tachycardic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Reviparin.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Opipramol is combined with Sibutramine.]
[N02AA02, opium, The risk or severity of serotonin syndrome can be increased when Opium is combined with Sibutramine.]
[R03CB03, metaproterenol, Sibutramine may increase the tachycardic activities of Orciprenaline.]
[B01AD07, reteplase, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Ancrod.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Sibutramine.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Sibutramine.]
[N02AA05, oxycodone, The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Sibutramine.]
[C01DX03, oxyfedrine, Sibutramine may increase the tachycardic activities of Oxyfedrine.]
[S01GA04, oxymetazoline, Sibutramine may increase the tachycardic activities of Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Sibutramine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Sibutramine.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Sibutramine.]
[B01AB09, danaparoid, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Sibutramine.]
[J04AB30, capreomycin, Sibutramine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the serotonergic activities of Sibutramine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[G04BD11, fesoterodine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Sibutramine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Penfluridol is combined with Sibutramine.]
[J01CE09, penicillin G procaine, Sibutramine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Sibutramine.]
[N05CA01, pentobarbital, The metabolism of Sibutramine can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Sibutramine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Sibutramine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Sibutramine.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Sibutramine.]
[N02AD02, phenazocine, The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Sibutramine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the serotonergic activities of Sibutramine.]
[B01AA02, phenindione, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Sibutramine can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Sibutramine.]
[B01AA04, phenprocoumon, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Sibutramine.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, Sibutramine may increase the tachycardic activities of Phenylephrine.]
[R01BA01, phenylpropanolamine, Sibutramine may increase the tachycardic activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Sibutramine can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, Sibutramine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Sibutramine is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Sibutramine.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Sibutramine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Sibutramine.]
[N06BX03, piracetam, Sibutramine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Sibutramine.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Sibutramine.]
[J05AG02, delavirdine, The metabolism of Sibutramine can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Sibutramine.]
[B01AC13, abciximab, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Alteplase.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Sibutramine.]
[C03AA05, polythiazide, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Sibutramine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Sibutramine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Sibutramine.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Sibutramine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Sibutramine.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Sibutramine.]
[P01BA03, primaquine, The metabolism of Sibutramine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Sibutramine can be increased when combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C01BA02, procainamide, Sibutramine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the serotonergic activities of Sibutramine.]
[L01XB01, procarbazine, Procarbazine may increase the serotonergic activities of Sibutramine.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sibutramine.]
[N04AA04, procyclidine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Sibutramine.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Sibutramine.]
[C01BC03, propafenone, The serum concentration of Propafenone can be increased when it is combined with Sibutramine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Sibutramine.]
[A03AB05, propantheline, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Sibutramine.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Sibutramine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Sibutramine.]
[N02AC04, propoxyphene, The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Sibutramine.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Sibutramine.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sibutramine.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Sibutramine.]
[B01AC09, epoprostenol, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Sibutramine.]
[R01BA02, pseudoephedrine, Sibutramine may increase the tachycardic activities of Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sibutramine.]
[N07XX07, dalfampridine, Sibutramine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Sibutramine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Sibutramine.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Sibutramine.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Sibutramine.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Sibutramine.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Sibutramine.]
[C01BA01, quinidine, Sibutramine may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Sibutramine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Sibutramine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Sibutramine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Sibutramine may increase the tachycardic activities of Rimiterol.]
[G02CA01, ritodrine, Sibutramine may increase the tachycardic activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Sibutramine.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sibutramine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Sibutramine.]
[N04BD01, selegiline, Selegiline may increase the serotonergic activities of Sibutramine.]
[J01GB08, sisomicin, Sibutramine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Sibutramine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Sibutramine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The serum concentration of Sotalol can be increased when it is combined with Sibutramine.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sibutramine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sibutramine.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[H02CA04, levoketoconazole, The metabolism of Sibutramine can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[R03BB01, ipratropium bromide, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
